Acquisition Announced

GSK acquisition of RAPT Therapeutics

US$2.2bn equity value

Announced 20 Jan 2026 · NASDAQ: RAPT · US$58.00 cash per share

Advisers

RAPT Therapeutics

Target

Financial adviser
Fairness opinion

GSK

Acquirer

Financial adviser
Legal adviser
Target
RAPT Therapeutics
Acquirer
GSK
Target based in
United States
Buyer based in
United Kingdom
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.